<DOC>
	<DOCNO>NCT00450385</DOCNO>
	<brief_summary>The investigator hypothesize survival newly diagnose DLBCL ( diffuse large B-cell lymphoma ) patient treat R-CHOP predict RNA protein gene expression presence biomarkers associate anti-tumor effect Rituximab .</brief_summary>
	<brief_title>Genes Predicting Outcome Patients With DLBCL Treated With Rituximab Combination Chemotherapy ( R-CHOP )</brief_title>
	<detailed_description>In phase II multi-institutional trial , investigator identify gene associate either good bad outcome DLBCL patient treat R-CHOP , construct robust predictive model base RNA extract paraffin specimen well immunohistochemistry examine predictive power new biomarkers associate anti-tumor effect rituximab . The acquisition fix tissue component uniformly treat prospective study also afford future study informative dataset .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>1 . Diagnosis diffuse large Bcell lymphoma , CD20positive , accord World Health Organization Classification , stag IIIV limited stage I disease bulky ( 10 cm ) International Prognostic Index ( IPI ) score &gt; 1 . 2 . Patients must prior chemotherapy , radiotherapy immunotherapy . A short course ( &lt; 2 week ) corticosteroid allow . 3 . Adequate paraffinembedded tumor specimen must available gene expression analysis immunohistochemistry prior initiation therapy . ( If specimen deem inadequate , subject retroactively screen fail , change treatment regimen ) . 4 . Baseline measurement evaluation must obtain within 4 week first treatment . 5 . Age &gt; 18 year . 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status 03 . 7 . Adequate organ function : White Blood Cells count ( WBC ) &gt; 2500/µL Absolute Neutrophil Count ( ANC ) &gt; 1000/µL ( unless due disease marrow ) platelet count &gt; 100,000/µL ( unless due disease marrow ) creatinine &lt; 2.0 mg/dL , bilirubin &lt; 1.5 mg/dL ( may 1.53.0 mg/dl due liver involvement lymphoma ) Serum Glutamic Oxaloacetic Transaminase ( SGOT ) / Serum Glutamic Pyruvic Transaminase ( SGPT ) &lt; 3 x upper limit normal . 8 . Female patient must pregnant breast feeding . 9 . Women childbearing potential men must strongly advise use accept effective method contraception . 10 . Patients must leave ventricular ejection fraction &gt; 45 % . 11 . Provision write informed consent . 1 . Patients second malignancy basal cell carcinoma skin situ carcinoma cervix unless tumor treat curative intent least two year previously ; ; patient continue free evidence recurrence . 2 . Patients HIV infection patient manage dedicated protocol . 3 . Patients active central nervous system ( CNS ) lymphoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
</DOC>